Androgen receptor splice variants and prostate cancer: From bench to bedside

Oncotarget

Volumn 8, Issue 11, 2017, Pages 18550-18576

  Wadosky, Kristine M ^a   Koochekpour, Shahriar ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

AR splice variant; Castration resistant; Clinical; Molecular biology; Prostate cancer

Indexed keywords

ABIRATERONE; ANDROGEN RECEPTOR; ANDROGEN RECEPTOR ANTAGONIST; ANTIANDROGEN; ENZALUTAMIDE; NICLOSAMIDE; AR PROTEIN, HUMAN; ISOPROTEIN;

ALTERNATIVE RNA SPLICING; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL TRIAL (TOPIC); DNA BINDING; DRUG EFFICACY; DRUG RESPONSE; EXON SKIPPING; GENETICALLY ENGINEERED MOUSE STRAIN; HUMAN; LIGAND BINDING; MOLECULAR BIOLOGY; NONHUMAN; OVERALL SURVIVAL; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; GENETICS; MALE; METABOLISM; PATHOLOGY; PROSTATE TUMOR;

ALTERNATIVE SPLICING; HUMANS; MALE; PROSTATIC NEOPLASMS; PROTEIN ISOFORMS; RECEPTORS, ANDROGEN;

EID: 85015247603     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.14537     Document Type: Article

References (97)

1. American Cancer Society. (2015). Cancer Facts & Figures 2015 In: Society AC, ed. (Atlanta: American Cancer Society).
2. Mohler J, Bahnson RR, Boston B, Busby JE, D'Amico A, Eastham JA, Enke CA, George D, Horwitz EM, Huben RP, KantoffP, Kawachi M, Kuettel M, et al. NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw. 2010; 8: 162-200. doi:
3. Mohler JL, Armstrong AJ, Bahnson RR, D'Amico AV, Davis BJ, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Hurwitz M, Kane CJ, Kawachi MH, et al. Prostate Cancer, Version 1.2016. J Natl Compr Canc Netw. 2016; 14: 19-30. doi:
4. Gleason DF. Classification of prostatic carcinomas. Cancer Chemother Rep. 1966; 50: 125-8. doi:
5. Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol. 1974; 111: 58-64. doi:
6. Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA, and the Grading C. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. Am J Surg Pathol. 2015. doi: 10.1097/PAS.0000000000000530.
7. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N, European Association of U. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol. 2014; 65: 124-37. doi: 10.1016/j.eururo.2013.09.046.
8. Makarov DV, Trock BJ, Humphreys EB, Mangold LA, Walsh PC, Epstein JI, Partin AW. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology. 2007; 69: 1095-101. doi: 10.1016/j. urology.2007.03.042.
9. Cooperberg MR, Broering JM, Carroll PR. Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis. J Natl Cancer Inst. 2009; 101: 878-87. doi: 10.1093/jnci/djp122.
10. Kollmeier MA, Zelefsky MJ. How to select the optimal therapy for early-stage prostate cancer. Crit Rev Oncol Hematol. 2012; 84 Suppl 1: e6-e15. doi: 10.1016/j. critrevonc.2012.12.002.
11. Romero-Otero J, Garcia-Gomez B, Duarte-Ojeda JM, Rodriguez-Antolin A, Vilaseca A, Carlsson SV, Touijer KA. Active surveillance for prostate cancer. Int J Urol. 2016; 23: 211-8. doi: 10.1111/iju.13016.
12. McLeod DG. Hormonal therapy: historical perspective to future directions. Urology. 2003; 61: 3-7. doi: 10.1016/S0090-4295(02)02393-2.
13. Wadosky KM, Koochekpour S. Therapeutic Rationales, Progresses, Failures, and Future Directions for Advanced Prostate Cancer. Int J Biol Sci. 2016; 12: 409-26. doi: doi:10.7150/ijbs.14090.
14. Huggins C, Hodges C. Studies on Prostatic Cancer. I. The Effect of Castration, of Estrogen and of Androgen Injection on Serum Phosphatases in Metastatic Carcinoma of the Prostate. Cancer Research. 1941; 1: 293-7. doi:
15. SharifiN, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA. 2005; 294: 238-44. doi: 10.1001/jama.294.2.238.
16. Dehm SM, Tindall DJ. Molecular regulation of androgen action in prostate cancer. J Cell Biochem. 2006; 99: 333-44. doi: 10.1002/jcb.20794.
17. Cookson MS, Roth BJ, Dahm P, Engstrom C, Freedland SJ, Hussain M, Lin DW, Lowrance WT, Murad MH, Oh WK, Penson DF, Kibel AS. Castration-resistant prostate cancer: AUA Guideline. J Urol. 2013; 190: 429-38. doi: 10.1016/j. juro.2013.05.005.
18. Cookson MS, Lowrance WT, Murad MH, Kibel AS, American Urological A. Castration-resistant prostate cancer: AUA guideline amendment. J Urol. 2015; 193: 491-9 doi: 10.1016/j.juro.2014.10.104.
19. Lowrance WT, Roth BJ, Kirkby E, Murad MH, Cookson MS. Castration-Resistant Prostate Cancer: AUA Guideline Amendment 2015. J Urol. 2016; 195: 1444-52. doi: 10.1016/j.juro.2015.10.086.
20. Harris WP, Mostaghel EA, Nelson PS, Montgomery B. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol. 2009; 6: 76-85. doi: 10.1038/ncpuro1296.
21. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB, Jr., Saad F, Staffurth JN, Mainwaring P, Harland S, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011; 364: 1995-2005. doi: 10.1056/NEJMoa1014618.
22. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013; 368: 138-48. doi: 10.1056/NEJMoa1209096.
23. Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, Davis ID, de Bono JS, Evans CP, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014; 371: 424-33. doi: 10.1056/NEJMoa1405095.
24. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Flechon A, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012; 367: 1187-97. doi: 10.1056/NEJMoa1207506.
25. Wadosky KM, Koochekpour S. Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer. Oncotarget. 2016;7:64447-64470. doi: 10.18632/oncotarget.10901.
26. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA, Investigators TAX. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004; 351: 1502-12. doi: 10.1056/NEJMoa040720.
27. Petrylak DP, Tangen CM, Hussain MH, Lara PN, Jr., Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004; 351: 1513-20. doi: 10.1056/NEJMoa041318.
28. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 2008; 26: 242-5 doi: 10.1200/JCO.2007.12.4008.
29. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castrationresistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010; 376: 1147-54. doi: 10.1016/S0140-6736(10)61389-X.
30. Koochekpour S. Androgen receptor signaling and mutations in prostate cancer. Asian J Androl. 2010; 12: 639-57. doi: 10.1038/aja.2010.89.
31. Heemers HV, Tindall DJ. Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr Rev. 2007; 28: 778-808. doi: 10.1210/er.2007-0019.
32. van der Steen T, Tindall DJ, Huang H. Posttranslational modification of the androgen receptor in prostate cancer. Int J Mol Sci. 2013; 14: 14833-59. doi: 10.3390/ijms140714833.
33. Dehm SM, Tindall DJ. Alternatively spliced androgen receptor variants. Endocr Relat Cancer. 2011; 18: R183-96. doi: 10.1530/ERC-11-0141.
34. Sartor O, Dong Y. Androgen receptor variant-7: an important predictive biomarker in castrate resistant prostate cancer. Asian J Androl. 2015; 17: 439-40. doi: 10.4103/1008-682X.145069.
35. Markowski MC, Frick KD, Eshleman JR, Luo J, Antonarakis ES. Cost-savings analysis of AR-V7 testing in patients with metastatic castration-resistant prostate cancer eligible for treatment with abiraterone or enzalutamide. Prostate. 2016. doi: 10.1002/pros.23232.
36. Maughan BL, Antonarakis ES. Clinical Relevance of Androgen Receptor Splice Variants in Castration-Resistant Prostate Cancer. Curr Treat Options Oncol. 2015; 16: 57. doi: 10.1007/s11864-015-0375-z.
37. Gregory CW, He B, Wilson EM. The putative androgen receptor-A form results from in vitro proteolysis. J Mol Endocrinol. 2001; 27: 309-19. doi: 10.1677/jme.0.0270309.
38. Haile S, Sadar MD. Androgen receptor and its splice variants in prostate cancer. Cell Mol Life Sci. 2011; 68: 3971-81. doi: 10.1007/s00018-011-0766-7.
39. Lu C, Luo J. Decoding the androgen receptor splice variants. Transl Androl Urol. 2013; 2: 178-86. doi: 10.3978/j.issn.2223-4683.2013.09.08.
40. Ahrens-Fath I, Politz O, Geserick C, Haendler B. Androgen receptor function is modulated by the tissue-specific AR45 variant. FEBS J. 2005; 272: 74-84. doi: 10.1111/j.1742-4658.2004.04395.x.
41. Jagla M, Feve M, Kessler P, Lapouge G, Erdmann E, Serra S, Bergerat JP, Ceraline J. A splicing variant of the androgen receptor detected in a metastatic prostate cancer exhibits exclusively cytoplasmic actions. Endocrinology. 2007; 148: 4334-43. doi: 10.1210/en.2007-0446.
42. Ceraline J, Erdmann E, Erbs P, Deslandres-Cruchant M, Jacqmin D, Duclos B, Klein-Soyer C, Dufour P, Bergerat JP. A yeast-based functional assay for the detection of the mutant androgen receptor in prostate cancer. Eur J Endocrinol. 2003; 148: 99-110. doi: 10.1530/eje.0.1480099.
43. Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res. 2008; 68: 5469-77. doi: 10.1158/0008-5472.CAN-08-0594.
44. Hu R, Dunn TA, Wei S, Isharwal S, Veltri RW, Humphreys E, Han M, Partin AW, Vessella RL, Isaacs WB, Bova GS, Luo J. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormonerefractory prostate cancer. Cancer Res. 2009; 69: 16-22. doi: 10.1158/0008-5472.CAN-08-2764.
45. Guo Z, Yang X, Sun F, Jiang R, Linn DE, Chen H, Chen H, Kong X, Melamed J, Tepper CG, Kung HJ, Brodie AM, Edwards J, et al. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res. 2009; 69: 2305-13. doi: 10.1158/0008-5472.CAN-08-3795.
46. Shourideh M, DePriest A, Mohler JL, Wilson EM, Koochekpour S. Characterization of fibroblast-free CWRR1ca castration-recurrent prostate cancer cell line. Prostate. 2016 doi: 10.1002/pros.23190.
47. Sun S, Sprenger CC, Vessella RL, Haugk K, Soriano K, Mostaghel EA, Page ST, Coleman IM, Nguyen HM, Sun H, Nelson PS, Plymate SR. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest. 2010; 120: 2715-30. doi: 10.1172/JCI41824.
48. Chan SC, Li Y, Dehm SM. Androgen receptor splice variants activate androgen receptor target genes and support aberrant prostate cancer cell growth independent of canonical androgen receptor nuclear localization signal. J Biol Chem. 2012; 287: 19736-49. doi: 10.1074/jbc. M112.352930.
49. Hu R, Isaacs WB, Luo J. A snapshot of the expression signature of androgen receptor splicing variants and their distinctive transcriptional activities. Prostate. 2011; 71: 1656-67. doi: 10.1002/pros.21382.
50. Kwegyir-Afful AK, Senthilmurugan R, Purushottamachar P, Ramamurthy VP, Njar VC. Galeterone and VNPT55 induce proteasomal degradation of AR/AR-V7, induce significant apoptosis via cytochrome c release and suppress growth of castration resistant prostate cancer xenografts in vivo. Oncotarget. 2015;6:27440-60. doi: 10.18632/oncotarget.4578.
51. Cao B, Qi Y, Zhang G, Xu D, Zhan Y, Alvarez X, Guo Z, Fu X, Plymate SR, Sartor O, Zhang H, Dong Y. Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy. Oncotarget. 2014; 5: 1646-56. doi: 10.18632/oncotarget.1802.
52. Peacock SO, Fahrenholtz CD, Burnstein KL. Vav3 enhances androgen receptor splice variant activity and is critical for castration-resistant prostate cancer growth and survival. Mol Endocrinol. 2012; 26: 1967-79. doi: 10.1210/me.2012-1165.
53. Watson PA, Chen YF, Balbas MD, Wongvipat J, Socci ND, Viale A, Kim K, Sawyers CL. Constitutively active androgen receptor splice variants expressed in castrationresistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci U S A. 2010; 107: 16759-65. doi: 10.1073/pnas.1012443107.
54. Hornberg E, Ylitalo EB, Crnalic S, Antti H, Stattin P, Widmark A, Bergh A, Wikstrom P. Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival. PLoS One. 2011; 6: e19059. doi: 10.1371/journal. pone.0019059.
55. Baugh LR, Hill AA, Brown EL, Hunter CP. Quantitative analysis of mRNA amplification by in vitro transcription. Nucleic Acids Res. 2001; 29: E29. doi: 10.1093/nar/29.5.e29.
56. Yang X, Guo Z, Sun F, Li W, Alfano A, Shimelis H, Chen M, Brodie AM, Chen H, Xiao Z, Veenstra TD, Qiu Y. Novel membrane-associated androgen receptor splice variant potentiates proliferative and survival responses in prostate cancer cells. J Biol Chem. 2011; 286: 36152-60. doi: 10.1074/jbc. M111.265124.
57. Hu R, Lu C, Mostaghel EA, Yegnasubramanian S, Gurel M, Tannahill C, Edwards J, Isaacs WB, Nelson PS, Bluemn E, Plymate SR, Luo J. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res. 2012; 72: 3457-62. doi: 10.1158/0008-5472.CAN-11-3892.
58. Nyquist MD, Li Y, Hwang TH, Manlove LS, Vessella RL, Silverstein KA, Voytas DF, Dehm SM. TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer. Proc Natl Acad Sci U S A. 2013; 110: 17492-7. doi: 10.1073/pnas.1308587110.
59. Chan SC, Selth LA, Li Y, Nyquist MD, Miao L, Bradner JE, Raj GV, Tilley WD, Dehm SM. Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies. Nucleic Acids Res. 2015; 43: 5880-97. doi: 10.1093/nar/gkv262.
60. Xu D, Zhan Y, Qi Y, Cao B, Bai S, Xu W, Gambhir SS, Lee P, Sartor O, Flemington EK, Zhang H, Hu CD, Dong Y. Androgen Receptor Splice Variants Dimerize to Transactivate Target Genes. Cancer Res. 2015; 75: 3663-71 doi: 10.1158/0008-5472.CAN-15-0381.
61. Centenera MM, Harris JM, Tilley WD, Butler LM. The contribution of different androgen receptor domains to receptor dimerization and signaling. Mol Endocrinol. 2008; 22: 2373-82. doi: 10.1210/me.2008-0017.
62. Day CP, Merlino G, Van Dyke T. Preclinical mouse cancer models: a maze of opportunities and challenges. Cell. 2015; 163: 39-53. doi: 10.1016/j.cell.2015.08.068.
63. Chung LW, Baseman A, Assikis V, Zhau HE. Molecular insights into prostate cancer progression: the missing link of tumor microenvironment. J Urol. 2005; 173: 10-20. doi: 10.1097/01.ju.0000141582.15218.10.
64. Wu X, Gong S, Roy-Burman P, Lee P, Culig Z. Current mouse and cell models in prostate cancer research. Endocr Relat Cancer. 2013; 20: R155-70. doi: 10.1530/ERC-12-0285.
65. Knuuttila M, Yatkin E, Kallio J, Savolainen S, Laajala TD, Aittokallio T, Oksala R, Hakkinen M, Keski-Rahkonen P, Auriola S, Poutanen M, Makela S. Castration induces up-regulation of intratumoral androgen biosynthesis and androgen receptor expression in an orthotopic VCaP human prostate cancer xenograft model. Am J Pathol. 2014; 184: 2163-73. doi: 10.1016/j.ajpath.2014.04.010.
66. Nastiuk KL, Liu H, Hamamura M, Muftuler LT, Nalcioglu O, Krolewski JJ. In vivo MRI volumetric measurement of prostate regression and growth in mice. BMC Urol. 2007; 7: 12. doi: 10.1186/1471-2490-7-12.
67. Yu Z, Chen S, Sowalsky AG, Voznesensky OS, Mostaghel EA, Nelson PS, Cai C, Balk SP. Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer. Clin Cancer Res. 2014; 20: 1590-600. doi: 10.1158/1078-0432.CCR-13-1863.
68. Cai C, Wang H, Xu Y, Chen S, Balk SP. Reactivation of androgen receptor-regulated TMPRSS2:ERG gene expression in castration-resistant prostate cancer. Cancer Res. 2009; 69: 6027-32. doi: 10.1158/0008-5472.CAN-09-0395.
69. Wei L, Wang J, Lampert E, Schlanger S, DePriest AD, Hu Q, Gomez EC, Murakam M, Glenn ST, Conroy J, Morrison C, Azabdaftari G, Mohler JL, et al. Intratumoral and Intertumoral Genomic Heterogeneity of Multifocal Localized Prostate Cancer Impacts Molecular Classifications and Genomic Prognosticators. Eur Urol. 2016 doi: 10.1016/j.eururo.2016.07.008.
70. Ellis WJ, Vessella RL, Buhler KR, Bladou F, True LD, Bigler SA, Curtis D, Lange PH. Characterization of a novel androgen-sensitive, prostate-specific antigen-producing prostatic carcinoma xenograft: LuCaP 23. Clin Cancer Res. 1996; 2: 1039-48. doi:
71. Corey E, Quinn JE, Buhler KR, Nelson PS, Macoska JA, True LD, Vessella RL. LuCaP 35: a new model of prostate cancer progression to androgen independence. Prostate. 2003; 55: 239-46. doi: 10.1002/pros.10198.
72. Schweizer MT, Antonarakis ES, Wang H, Ajiboye AS, Spitz A, Cao H, Luo J, Haffner MC, Yegnasubramanian S, Carducci MA, Eisenberger MA, Isaacs JT, Denmeade SR. Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study. Sci Transl Med. 2015; 7: 269ra2. doi: 10.1126/scitranslmed.3010563.
73. Mostaghel EA, Marck BT, Plymate SR, Vessella RL, Balk S, Matsumoto AM, Nelson PS, Montgomery RB. Resistance to CYP17A1 inhibition with abiraterone in castrationresistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res. 2011; 17: 5913-25. doi: 10.1158/1078-0432.CCR-11-0728.
74. Greenberg NM, DeMayo FJ, Sheppard PC, Barrios R, Lebovitz R, Finegold M, Angelopoulou R, Dodd JG, Duckworth ML, Rosen JM, et al. The rat probasin gene promoter directs hormonally and developmentally regulated expression of a heterologous gene specifically to the prostate in transgenic mice. Mol Endocrinol. 1994; 8: 230-9 doi: 10.1210/mend.8.2.8170479.
75. Liu G, Sprenger C, Sun S, Epilepsia KS, Haugk K, Zhang X, Coleman I, Nelson PS, Plymate S. AR variant ARv567es induces carcinogenesis in a novel transgenic mouse model of prostate cancer. Neoplasia. 2013; 15: 1009-17. doi: 10.1593/neo.13784.
76. Sun F, Chen HG, Li W, Yang X, Wang X, Jiang R, Guo Z, Chen H, Huang J, Borowsky AD, Qiu Y. Androgen receptor splice variant AR3 promotes prostate cancer via modulating expression of autocrine/paracrine factors. J Biol Chem. 2014; 289: 1529-39. doi: 10.1074/jbc. M113.492140.
77. Grabowska MM, DeGraffDJ, Yu X, Jin RJ, Chen Z, Borowsky AD, Matusik RJ. Mouse models of prostate cancer: picking the best model for the question. Cancer Metastasis Rev. 2014; 33: 377-97. doi: 10.1007/s10555-013-9487-8.
78. Terry S, Beltran H. The many faces of neuroendocrine differentiation in prostate cancer progression. Front Oncol. 2014; 4: 60. doi: 10.3389/fonc.2014.00060.
79. Efstathiou E, Titus M, Wen S, Hoang A, Karlou M, Ashe R, Tu SM, Aparicio A, Troncoso P, Mohler J, Logothetis CJ. Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer. Eur Urol. 2015; 67: 53-60. doi: 10.1016/j.eururo.2014.05.005.
80. Steinkamp MP, O'Mahony OA, Brogley M, Rehman H, Lapensee EW, Dhanasekaran S, Hofer MD, Kuefer R, Chinnaiyan A, Rubin MA, Pienta KJ, Robins DM. Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy. Cancer Res. 2009; 69: 4434-42. doi: 10.1158/0008-5472.CAN-08-3605.
81. Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G, Beltran H, Abida W, Bradley RK, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015; 161: 1215-28. doi: 10.1016/j.cell.2015.05.001.
82. Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, Lotan TL, Zheng Q, De Marzo AM, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014; 371: 1028-38. doi: 10.1056/NEJMoa1315815.
83. van der Toom EE, Verdone JE, Gorin MA, Pienta KJ. Technical challenges in the isolation and analysis of circulating tumor cells. Oncotarget. 2016;7:62754-62766. doi: 10.18632/oncotarget.11191.
84. Steinestel J, Luedeke M, Arndt A, Schnoeller TJ, Lennerz JK, Wurm C, Maier C, Cronauer MV, Steinestel K, Schrader AJ. Detecting predictive androgen receptor modifications in circulating prostate cancer cells. Oncotarget. 2015. doi: 10.18632/oncotarget.3925.
85. Liu X, Ledet E, Li D, Dotiwala A, Steinberger A, Feibus A, Li J, Qi Y, Silberstein J, Lee B, Dong Y, Sartor O, Zhang H. A Whole Blood Assay for AR-V7 and ARv567es in Prostate Cancer Patients. J Urol. 2016. doi: 10.1016/j. juro.2016.06.095.
86. Todenhofer T, Azad A, Stewart C, Gao J, Eigl BJ, Gleave ME, Joshua AM, Black PC, Chi KN. AR-V7 transcripts in whole blood RNA of patients with metastatic castration resistant prostate cancer correlate with response to Abiraterone acetate. J Urol. 2016. doi: 10.1016/j. juro.2016.06.094.
87. Qu F, Xie W, Nakabayashi M, Zhang H, Jeong SH, Wang X, Komura K, Sweeney CJ, Sartor O, Lee GM, KantoffPW. Association of AR-V7 and prostate specific antigen RNA levels in blood with efficacy of abiraterone acetate and enzalutamide treatment in men with prostate cancer. Clin Cancer Res. 2016. doi: 10.1158/1078-0432.CCR-16-1070.
88. Hudecova I. Digital PCR analysis of circulating nucleic acids. Clin Biochem. 2015; 48: 948-56. doi: 10.1016/j. clinbiochem.2015.03.015.
89. Bernemann C, Schnoeller TJ, Luedeke M, Steinestel K, Boegemann M, Schrader AJ, Steinestel J. Expression of AR-V7 in Circulating Tumour Cells Does Not Preclude Response to Next Generation Androgen Deprivation Therapy in Patients with Castration Resistant Prostate Cancer. Eur Urol. 2016. doi: 10.1016/j.eururo.2016.07.021.
90. Antonarakis ES, Chandhasin C, Osbourne E, Luo J, Sadar MD, Perabo F. Targeting the N-Terminal Domain of the Androgen Receptor: A New Approach for the Treatment of Advanced Prostate Cancer. Oncologist. 2016. doi: 10.1634/theoncologist.2016-0161.
91. Andersen RJ, Mawji NR, Wang J, Wang G, Haile S, Myung JK, Watt K, Tam T, Yang YC, Banuelos CA, Williams DE, McEwan IJ, Wang Y, et al. Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the aminoterminus domain of the androgen receptor. Cancer Cell. 2010; 17: 535-46. doi: 10.1016/j.ccr.2010.04.027.
92. Myung JK, Banuelos CA, Fernandez JG, Mawji NR, Wang J, Tien AH, Yang YC, Tavakoli I, Haile S, Watt K, McEwan IJ, Plymate S, Andersen RJ, et al. An androgen receptor N-terminal domain antagonist for treating prostate cancer. J Clin Invest. 2013; 123: 2948-60. doi: 10.1172/JCI66398.
93. Liu C, Lou W, Zhu Y, Nadiminty N, Schwartz CT, Evans CP, Gao AC. Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer. Clin Cancer Res. 2014; 20: 3198-210. doi: 10.1158/1078-0432.CCR-13-3296.
94. Liu C, Armstrong C, Zhu Y, Lou W, Gao AC. Niclosamide enhances abiraterone treatment via inhibition of androgen receptor variants in castration resistant prostate cancer. Oncotarget. 2016;7:32210-20. doi: 10.18632/oncotarget.8493.
95. Njar VC, Brodie AM. Discovery and development of Galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer. J Med Chem. 2015; 58: 2077-87. doi: 10.1021/jm501239f.
96. Handratta VD, Vasaitis TS, Njar VC, Gediya LK, Kataria R, Chopra P, Newman D, Jr., Farquhar R, Guo Z, Qiu Y, Brodie AM. Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model. J Med Chem. 2005; 48: 2972-84. doi: 10.1021/jm040202w.
97. Yu Z, Cai C, Gao S, Simon NI, Shen HC, Balk SP. Galeterone prevents androgen receptor binding to chromatin and enhances degradation of mutant androgen receptor. Clin Cancer Res. 2014; 20: 4075-85. doi: 10.1158/1078-0432. CCR-14-0292.